Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.

Abstract

The dolastatin series of unique peptides, originally discovered as constituents of the sea hare Dolabella auricularia, is of increasing importance in providing biological leads, especially to new and useful anticancer drugs. Dolastatin 10 and three analogues, minor structural modifications designated auristatins, are currently in human cancer clinical trials. The present study was undertaken to explore delivery to the cancer sites by way of phosphate or quinoline modifications. The initial objectives, auristatin TP as sodium phosphate 3b (GI50 10(-2)-10(-4) μg/mL), auristatin 2-AQ (4, GI50 10(-2)-10(-3) μg/mL), and auristatin 6-AQ (5, GI50 10(-4) μg/mL), exhibited superior cancer cell growth inhibitory properties.

• Authors: George R Pettit, Fiona Hogan, Steven Toms
• Journal: Journal of natural products (J Nat Prod) Vol. 74 Issue 5 Pg. 962-8 (May 27 2011) ISSN: 1520-6025 [Electronic] United States
• PMID: 21534541 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Depsipeptides
• dolastatin 10

Topics

• Animals
• Antineoplastic Agents (chemistry, pharmacology)
• Clinical Trials as Topic
• Depsipeptides (chemistry, pharmacology)
• Drug Screening Assays, Antitumor
• Humans
• Leukemia P388
• Mice
• Molecular Structure